NL-OMON39500CompletedNot Applicable
Follow up ALIFE study - Follow up ALIFE
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 364
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •participation in the previously performed ALIFE study (Kaandorp, NEJM, 2010)
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Not Applicable
TWICE-Follow up studyprimary osteoporosisJPRN-UMIN000046026Sanzai Hospital82
Active, not recruiting
Not Applicable
The effect of ALFALIFE™ in reducing low-grade inflammatioow-grade inflammationNutritional, Metabolic, EndocrineChronic low-grade inflammationISRCTN12319920Digitcal S.r.l.24
Completed
Not Applicable
The follow up study of "Phase l / ll Study of S-1+oxaliplatin (SOX)+cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type (JACCRO CC-06)".metastatic colorectal cancerJPRN-UMIN000027014Japan Clinical Cancer Research Organization33
Active, not recruiting
Phase 1
ong-term efficacy and safety study to evaluate DX-2930 in preventing angioedema attacks in patients with Type I and Type II hereditary angioedema (HAE)Type I and Type II Hereditary Angioedema (HAE)MedDRA version: 23.1Level: LLTClassification code 10075280Term: Hereditary angioedema attackSystem Organ Class: 100000004850EUCTR2015-005255-27-ITDYAX CORP.212
Active, not recruiting
Phase 1
ong-term efficacy and safety study to evaluate DX-2930 in preventing angioedema attacks in patients with Type I and Type II hereditary angioedema (HAE)Type I and Type II Hareditary Angioedema (HAE)MedDRA version: 20.0Level: LLTClassification code 10075280Term: Hereditary angioedema attackSystem Organ Class: 100000004850EUCTR2015-005255-27-DEDyax Corp., (an indirect, wholly-owned subsidiary of Shire plc.)225